ONA completes tens of millions in Angel round financing, with Riemann Hypothesis serving as the exclusive financial advisor for this round

Recently, ONA GeneHeal Pharma, the world's first industrialization technology platform for genome-edited miniature pig xenotransplantation and a company with exclusive large-scale gene editing technological tools, announced the completion of a tens of millions angel round financing. This round was led by DAAN Incubator, with Riemann Hypothesis serving as the exclusive financial advisor for this financing.

Founded in July 2024 and headquartered in Hengqin, ONA is a biotechnology high-tech company in the field of organ transplantation. ONA's vision is to "Create a World of Donor Freedom!" and it operates the world's first industrialization platform for genome-edited miniature pig xenotransplantation. ONA holds exclusive core technology patents in large-scale gene editing and cell quantitative partial reprogramming. Upholding the philosophy of "One Pig Fits All," it aims to build a large-scale genome-edited pig platform to serve as an unlimited, industrializable source of donors for nearly all clinical cell, tissue, and organ transplants, fundamentally addressing the global shortage of donor organs.

The core technology of ONA integrates gene editing, quantitative partial reprogramming, mRNA technology, and Piggybac technology, enabling genomic edits of over 100 kb to 100 Mb, thereby breaking through the international technological bottleneck of large-scale genome editing in pigs. Based on this technology platform, ONA's inaugural product, the Rescuer gene-edited pig skin—HuRescu™ Skin—is a xenotransplantation skin product. This xenotransplanted skin contains components such as hair follicles, blood vessels, sweat glands, melanocytes, and Langerhans cells found in normal skin. It promotes skin regeneration, restores skin function, and offers core advantages such as rapid healing and low immune rejection. This pipeline has already completed nearly a hundred clinical IIT trials.

ONA's unique large-scale genome-edited pig skin is currently the closest alternative to human cadaver skin (the current gold standard for treatment). ONA's future R&D pipeline will expand from skin to other vital organs such as cartilage, bone, liver, heart, kidney, and lungs. These advantages have also gained high recognition from the capital market, enabling the company to efficiently complete its angel round financing. The funds from this round will primarily be used for platform construction, advancing the R&D of existing product pipelines, and IND applications.

The core team of ONA comprises top R&D members from both Chinese and international industry and scientific communities. Among them, founder Dr. Wang Gang holds a Ph.D. from the University of Edinburgh (under the guidance of Professor Ian Wilmut, known as the father of Dolly the cloned sheep), and served as a postdoctoral fellow and lecturer at Boston Children's Hospital, Harvard University (under the guidance of CRISPR-Cas9 gene editing pioneer Professor George Church). He also accumulated extensive frontier and solid expertise in core xenotransplantation technologies as Chief Scientist at Egenesis, a U.S. pioneer in xenotransplantation regenerative medicine. ONA's scientific advisory team includes Professor Robert Langer, founder of Moderna and a member of the U.S. National Academies (National Academy of Sciences, National Academy of Engineering, and National Academy of Medicine), as well as Professor William Pu, a pioneer in CRISPR gene editing and mRNA technology and Director of the Heart Center at Boston Children's Hospital, Harvard University.